Pharmaceutical News and Articles

Depression Can Speed Onset of Chronic Illnesses, Study Finds

Depression hits the whole body, speeding the onset of long-term physical ills as people age, new research contends. People who ve experienced depression are mor

Early Childhood Sun Exposure Linked to Lower Risk for Pediatric MS Relapse

Greater prenatal and early childhood sun exposure is associated with a lower risk for relapse among children with multiple sclerosis (MS), according to a study

Could Yogurt Lower Your Odds for Deadly Colon Cancers?

You may be less likely to develop an especially lethal form of colon cancer if you re a longtime consumer of yogurt, new research finds. Folks who ate two or mo

Enjoying Valentine's Day When a Loved One Has Alzheimer's

Love doesn t fade when one member of a family develops Alzheimer s disease, but times of intimacy like Valentine s Day can become tougher. Experts at the Alzhei

More Sunshine in Pregnancy, Infancy Could Benefit Kids With MS

Children who develop multiple sclerosis appear to fare better if they were exposed to safe amounts of summer sunshine as infants, new research shows. If their m

Ready for a Romantic Relationship? Your Friends' Opinions Matter

This Valentine s Day, are you ready for something real or still playing the field New research suggests your friends probably share similar notions about your r

Certain Birth Control Pills, Devices Linked to Higher Heart Risks

The most common formulation of birth control pills has been linked to a doubling of relative risk of heart attack and stroke, a new study finds. Contraceptive v

U.S. FDA Approves Pfizer’s Adcetris Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Spinogenix Completes Phase 2 Study of SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism, Showing Strong Efficacy Signal in Measures of Abnormal Brain Activity

LOS ANGELES, Calif., February 11, 2025 Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses

FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)